DDP ip Combined With AG in PDAC With Peritoneal Metastasis

Inclusion criteria

cohort A

Patients should meet the following criteria before treatment to be included in the trial:

• Voluntarily participate and sign the informed consent;
• Age ≥18 years old and ≤75 years old, gender is not limited;
• ECOG score ≤2 points;
• Pathological diagnosis of pancreatic adenocarcinoma;
• Advanced pancreatic cancer with intra-abdominal metastasis in imaging assessment, or intra-operative intra-operative findings of intra-abdominal metastasis;
• The time from the end of adjuvant chemotherapy after surgery is more than 6 months, or they have not received any form of anti-tumor therapy before, including interventional chemoembolization, ablation, radiotherapy, chemotherapy, and molecular targeted therapy;
• No serious abnormal blood system, heart, lung function and immune deficiency (refer to their respective standards);
• Blood routine indicators: white blood cells ≥3 × 109/L; absolute neutrophil count ≥1.5 × 109/L; platelets ≥100 × 109/L; hemoglobin ≥9 g/dL;
• Blood biochemical indexes: AST (SGOT), ALT (SGPT) ≤ 2.5 × upper limit of normal (ULN); total bilirubin (TBIL) ≤ ULN; serum creatinine (CRE) ≤ 1.5 × ULN;
• Coagulation function: prothrombin time (PT), international normalized ratio (INR) ≤ 1.5 × ULN;
• Able to comply with research visit plans and other protocol requirements.

Inclusion criteria

(Cohort B)

Patients should meet the following criteria before treatment to be included in the trial:

• Voluntarily participate and sign the informed consent;
• Age ≥18 years old and ≤75 years old, gender is not limited;
• ECOG score ≤2 points;
• Pathological diagnosis of pancreatic adenocarcinoma;
• malignant ascites with positive peritoneal cytology or Laparoscopic exploration processed.
• At least one systemic chemotherapy has been used;
• No serious abnormal blood system, heart, lung function and immune deficiency (refer to their respective standards);
• Blood routine indicators: white blood cells ≥3 × 109/L; absolute neutrophil count ≥1.5 × 109/L; platelets ≥100 × 109/L; hemoglobin ≥9 g/dL;
• Blood biochemical indexes: AST (SGOT), ALT (SGPT) ≤ 2.5 × upper limit of normal (ULN); total bilirubin (TBIL) ≤ ULN; serum creatinine (CRE) ≤ 1.5 × ULN;
• Coagulation function: prothrombin time (PT), international normalized ratio (INR) ≤ 1.5 × ULN;
• Able to comply with research visit plans and other protocol requirements.

Exclusion criteria

Patients were excluded from the study if they met any of the following criteria:

• Associated with other systemic malignant tumors;
• Single kidney, deformed kidney or poor renal compensation;
• Have used any other study drug within 7 days before chemotherapy;
• Patients with central nervous system disease, mental illness, unstable angina pectoris, congestive heart failure, severe arrhythmia and other serious diseases that cannot be controlled;
• There is a history of allergy to the study drug or drugs of similar structure;
• Patients who are using and require long-term use of warfarin anticoagulation.